Candel Therapeutics · 1 day ago
Senior/Principal Scientist – Analytical Development (Contract)
Needham, MA
Contract
Onsite
Senior Level, Lead/Staff
$170K/yr - $184K/yrCandel Therapeutics is a clinical-stage biopharma company developing innovative cancer immunotherapies. They are seeking a highly qualified Senior or Principal Scientist to support analytical development activities, focusing on laboratory operations, cell-based assays, and molecular methodologies.
BiotechnologyGeneticsHealth CareHealth DiagnosticsMedicalTherapeutics
No H1B
Responsibilities
Supervise and coordinate daily laboratory operations related to analytical development
Author and critically review analytical protocols, standard operating procedures (SOPs), and technical reports
Conduct comprehensive data analysis and ensure the accuracy and integrity of analytical results
Lead investigations into out-of-specification (OOS) results and deviations, including root cause analysis and implementation of corrective actions
Provide training and technical guidance to team members on the implementation of new assay methodologies
Collaborate with cross-functional stakeholders to ensure alignment of analytical deliverables with broader program objectives
Ensure all laboratory activities are conducted in compliance with applicable GxP regulations and ICH guidelines
Qualification
Required
M.S. or Ph.D. in Analytical Biochemistry, Molecular Biology, or a related scientific discipline; equivalent industry experience may be considered
Demonstrated expertise in analytical development, with a focus on cell-based and molecular assay techniques
Proficiency in GxP-compliant laboratory practices and familiarity with ICH regulatory standards
Strong analytical, organizational, and scientific writing skills
Availability to work on-site with 40% of time dedicated to laboratory-based activities
All applicants must be authorized to work in the United States and must not require sponsorship
Company
Candel Therapeutics
Candel Therapeutics develops cancer immunotherapies designed to improve the lives of cancer patients and their families.
Founded in 1999
11-50 employees
Funding
Current Stage
Public CompanyTotal Funding
$321.9MKey Investors
Trinity CapitalSilicon Valley BankNorthpond Ventures
2025-10-14Post Ipo Debt· $50M
2025-06-24Post Ipo Equity· $15M
2024-12-12Post Ipo Equity· $92M
Leadership Team
Nathan Caffo
Chief Business Officer
Recent News
24-7 Press Release Newswire
2025-11-27
Candel Therapeutics, Inc
2025-11-14
2025-11-14
Company data provided by crunchbase